Korro Bio, Inc. Stock price

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
88.53 USD +1.82% Intraday chart for Korro Bio, Inc. +36.75% +84.71%
Sales 2024 * - Sales 2025 * - Capitalization 710M
Net income 2024 * -79M Net income 2025 * -85M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-11.4 x
P/E ratio 2025 *
-10.6 x
Employees 96
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.22%
More Fundamentals * Assessed data
Dynamic Chart
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Struggle After New Records DJ
North American Morning Briefing : Inflation -2- DJ
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120 MT
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency CI
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein MT
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee CI
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target MT
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index CI
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders. CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Baird Downgrades Frequency Therapeutics to Neutral From Outperform MT
More news
1 day+1.82%
1 week+36.75%
Current month+83.29%
1 month+87.96%
3 months+75.34%
Current year+84.71%
More quotes
1 week
62.56
Extreme 62.555
97.91
1 month
46.61
Extreme 46.6125
97.91
Current year
38.75
Extreme 38.7465
97.91
1 year
14.00
Extreme 14
97.91
3 years
14.00
Extreme 14
97.91
5 years
14.00
Extreme 14
97.91
10 years
14.00
Extreme 14
97.91
More quotes
Date Price Change Volume
24-03-27 88.53 +1.82% 48,554
24-03-26 86.95 +18.43% 51,857
24-03-25 73.42 +12.92% 44,503
24-03-22 65.02 +0.03% 65,212
24-03-21 65 +0.40% 20,025

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The Company's focus areas include the liver and central nervous system (CNS).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
88.53 USD
Average target price
122.5 USD
Spread / Average Target
+38.37%
Consensus
  1. Stock
  2. Equities
  3. Stock Korro Bio, Inc. - Nasdaq